{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:35:05Z","timestamp":1792704905172,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T00:00:00Z","timestamp":1545868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["11472"],"award-info":[{"award-number":["11472"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012331","name":"Agentschap Innoveren en Ondernemen","doi-asserted-by":"publisher","award":["IWT.141396"],"award-info":[{"award-number":["IWT.141396"]}],"id":[{"id":"10.13039\/100012331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["SBOS006617N"],"award-info":[{"award-number":["SBOS006617N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0E1917N"],"award-info":[{"award-number":["G0E1917N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12035-018-1449-2","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T03:22:56Z","timestamp":1545880976000},"page":"5273-5286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization"],"prefix":"10.1007","volume":"56","author":[{"given":"T.","family":"De Wit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Baekelandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lobbestael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,27]]},"reference":[{"key":"1449_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","volume":"44","author":"C Pais\u00e1n-Ru\u00edz","year":"2004","unstructured":"Pais\u00e1n-Ru\u00edz C, Jain S, Evans EW et al (2004) Cloning of the gene containing mutations that cause PARK8 -linked Parkinson\u2019s disease. Neuron 44:595\u2013600","journal-title":"Neuron"},{"key":"1449_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","volume":"44","author":"A Zimprich","year":"2004","unstructured":"Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601\u2013607. \n                    https:\/\/doi.org\/10.1016\/j.neuron.2004.11.005","journal-title":"Neuron"},{"key":"1449_CR3","doi-asserted-by":"publisher","unstructured":"Di Fonzo A, Roh\u00e9 CF, Ferreira J, Chien HF, Vacca L, Stocchi F, Guedes L, Fabrizio E et al (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson\u2019s disease. Lancet 365:412\u2013415. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(05)17829-5","DOI":"10.1016\/S0140-6736(05)17829-5"},{"key":"1449_CR4","doi-asserted-by":"publisher","first-page":"6455","DOI":"10.1111\/j.1742-4658.2009.07344.x","volume":"276","author":"U Kumari","year":"2009","unstructured":"Kumari U, Tan EK (2009) LRRK2 in Parkinson\u2019s disease: genetic and clinical studies from patients. FEBS J 276:6455\u20136463. \n                    https:\/\/doi.org\/10.1111\/j.1742-4658.2009.07344.x","journal-title":"FEBS J"},{"key":"1449_CR5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ng.485","volume":"41","author":"W Satake","year":"2009","unstructured":"Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T et al (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson\u2019s disease. Nat Genet 41:1303\u20131307. \n                    https:\/\/doi.org\/10.1038\/ng.485","journal-title":"Nat Genet"},{"key":"1449_CR6","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/ng.487","volume":"41","author":"J Sim\u00f3n-S\u00e1nchez","year":"2009","unstructured":"Sim\u00f3n-S\u00e1nchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P et al (2009) Genome-wide association study reveals genetic risk underlying Parkinson\u2019s disease. Nat Genet 41:1308\u20131312. \n                    https:\/\/doi.org\/10.1038\/ng.487","journal-title":"Nat Genet"},{"key":"1449_CR7","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S1474-4422(11)70175-2","volume":"10","author":"OA Ross","year":"2011","unstructured":"Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S et al (2011) Association of LRRK2 exonic variants with susceptibility to Parkinson\u2019s disease: a case\u2013control study. Lancet Neurol 10:898\u2013908. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(11)70175-2","journal-title":"Lancet Neurol"},{"key":"1449_CR8","doi-asserted-by":"publisher","unstructured":"Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E et al (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson\u2019s disease genetics: the PDGene database. PLoS Genet 8:e1002548. \n                    https:\/\/doi.org\/10.1371\/journal.pgen.1002548","DOI":"10.1371\/journal.pgen.1002548"},{"key":"1449_CR9","doi-asserted-by":"publisher","unstructured":"Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E et al (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease. Nat Genet 46:989\u2013993. \n                    https:\/\/doi.org\/10.1038\/ng.3043","DOI":"10.1038\/ng.3043"},{"key":"1449_CR10","doi-asserted-by":"publisher","unstructured":"Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: a case-control study. Lancet Neurol 7:583\u2013590. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(08)70117-0","DOI":"10.1016\/S1474-4422(08)70117-0"},{"key":"1449_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ajmg.b.32452","volume":"171","author":"IF Mata","year":"2016","unstructured":"Mata IF, Davis MY, Lopez AN, Dorschner MO, Martinez E, Yearout D, Cholerton BA, Hu SC et al (2016) The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson\u2019s disease, adds to the complexity of a mutational hotspot. Am J Med Genet Neuropsychiatr Genet 171:925\u2013930. \n                    https:\/\/doi.org\/10.1002\/ajmg.b.32452","journal-title":"Am J Med Genet Neuropsychiatr Genet"},{"key":"1449_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.tins.2006.03.006","volume":"29","author":"IF Mata","year":"2006","unstructured":"Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA (2006) LRRK2 in Parkinson\u2019s disease: protein domains and functional insights. Trends Neurosci 29:286\u2013293. \n                    https:\/\/doi.org\/10.1016\/j.tins.2006.03.006","journal-title":"Trends Neurosci"},{"key":"1449_CR13","doi-asserted-by":"publisher","first-page":"164ra161","DOI":"10.1126\/scitranslmed.3004485","volume":"4","author":"Z Sheng","year":"2012","unstructured":"Sheng Z, Zhang S, Bustos D, Kleinheinz T, le Pichon CE, Dominguez SL, Solanoy HO, Drummond J et al (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med 4:164ra161. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3004485","journal-title":"Sci Transl Med"},{"key":"1449_CR14","doi-asserted-by":"publisher","unstructured":"Reynolds A, Doggett EA, Riddle SM, Lebakken CS, Nichols RJ (2014) LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status. Front Mol Neurosci 7(54). \n                    https:\/\/doi.org\/10.3389\/fnmol.2014.00054","DOI":"10.3389\/fnmol.2014.00054"},{"key":"1449_CR15","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12813","volume":"5","author":"M Steger","year":"2016","unstructured":"Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, Wachter S, Lorentzen E et al (2016) Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5:e12813. \n                    https:\/\/doi.org\/10.7554\/eLife.12813","journal-title":"Elife"},{"key":"1449_CR16","doi-asserted-by":"publisher","unstructured":"Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I, Berti G et al (2017) Age-dependent dopamine transporter dysfunction and Serine129 phospho-\u03b1-synuclein overload in G2019S LRRK2 mice. Acta Neuropathol Commun 5(22). \n                    https:\/\/doi.org\/10.1186\/s40478-017-0426-8","DOI":"10.1186\/s40478-017-0426-8"},{"key":"1449_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.nbd.2006.04.001","volume":"23","author":"E Greggio","year":"2006","unstructured":"Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A et al (2006) Kinase activity is required for the toxic effects of mutant LRRK2\/dardarin. Neurobiol Dis 23:329\u2013341. \n                    https:\/\/doi.org\/10.1016\/j.nbd.2006.04.001","journal-title":"Neurobiol Dis"},{"key":"1449_CR18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/nn1776","volume":"9","author":"WW Smith","year":"2006","unstructured":"Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231\u20131233. \n                    https:\/\/doi.org\/10.1038\/nn1776","journal-title":"Nat Neurosci"},{"key":"1449_CR19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nm.2199","volume":"16","author":"BD Lee","year":"2010","unstructured":"Lee BD, Shin J-H, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA et al (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson\u2019s disease. Nat Med 16:998\u20131000. \n                    https:\/\/doi.org\/10.1038\/nm.2199","journal-title":"Nat Med"},{"key":"1449_CR20","doi-asserted-by":"publisher","first-page":"19433","DOI":"10.1074\/jbc.M115.660001","volume":"290","author":"JPL Daher","year":"2015","unstructured":"Daher JPL, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, Needle E, Chen Y et al (2015) Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates a-synuclein gene-induced neurodegeneration. J Biol Chem 290:19433\u201319444. \n                    https:\/\/doi.org\/10.1074\/jbc.M115.660001","journal-title":"J Biol Chem"},{"key":"1449_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/hmg\/dds431","volume":"22","author":"C Yao","year":"2013","unstructured":"Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, Alessi DR, Zhu X et al (2013) Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum Mol Genet 22:328\u2013344. \n                    https:\/\/doi.org\/10.1093\/hmg\/dds431","journal-title":"Hum Mol Genet"},{"key":"1449_CR22","doi-asserted-by":"publisher","first-page":"141ra90","DOI":"10.1126\/scitranslmed.3003985","volume":"4","author":"O Cooper","year":"2012","unstructured":"Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, McLean JR, Carrillo-Reid L et al (2012) Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson\u2019s disease. Sci Transl Med 4:141ra90. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3003985","journal-title":"Sci Transl Med"},{"key":"1449_CR23","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1212\/WNL.0000000000002436","volume":"86","author":"KB Fraser","year":"2016","unstructured":"Fraser KB, Moehle MS, Alcalay RN, West AB (2016) Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology 86:994\u2013999. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000002436","journal-title":"Neurology"},{"key":"1449_CR24","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/mds.26686","volume":"31","author":"KB Fraser","year":"2016","unstructured":"Fraser KB, Rawlins AB, Clark RG, Alcalay RN, Standaert DG, Liu N, Parkinson\u2019s Disease Biomarker Program Consortium, West AB (2016) Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson\u2019s disease. Mov Disord 31:1543\u20131550. \n                    https:\/\/doi.org\/10.1002\/mds.26686","journal-title":"Mov Disord"},{"key":"1449_CR25","doi-asserted-by":"publisher","unstructured":"Di Maio R, Hoffman EK, Rocha EM, Keeney MT, Sanders LH, De Miranda BR, Zharikov A, Van Laar A et al (2018) LRRK2 activation in idiopathic Parkinson\u2019s disease. Sci Transl Med 10:eaar5429. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aar5429","DOI":"10.1126\/scitranslmed.aar5429"},{"key":"1449_CR26","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1517\/13543776.2012.729041","volume":"22","author":"X Deng","year":"2012","unstructured":"Deng X, Choi HG, Buhrlage SJ, Gray NS (2012) Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 \u2013 2011). Expert Opin Ther Pat 22:1415\u20131426. \n                    https:\/\/doi.org\/10.1517\/13543776.2012.729041","journal-title":"Expert Opin Ther Pat"},{"key":"1449_CR27","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1517\/13543776.2014.907275","volume":"24","author":"RR Kethiri","year":"2014","unstructured":"Kethiri RR, Bakthavatchalam R (2014) Leucine-rich repeat kinase 2 inhibitors : a review of recent patents (2011-2013). Expert Opin Ther Pat 24:745\u2013757","journal-title":"Expert Opin Ther Pat"},{"key":"1449_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1042\/BJ20141305","volume":"469","author":"J Zhao","year":"2015","unstructured":"Zhao J, Molitor TP, Langston JW, Nichols RJ (2015) LRRK2 dephosphorylation increases its ubiquitination. Biochem J 469:107\u2013120. \n                    https:\/\/doi.org\/10.1042\/BJ20141305","journal-title":"Biochem J"},{"key":"1449_CR29","doi-asserted-by":"publisher","unstructured":"Lobbestael E, Civiero L, De Wit T, Taymans J-M, Greggio E, Baekelandta V(2016) Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation. Sci Rep 6:33897. \n                    https:\/\/doi.org\/10.1038\/srep33897","DOI":"10.1038\/srep33897"},{"key":"1449_CR30","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1093\/hmg\/ddr348","volume":"20","author":"MC Herzig","year":"2011","unstructured":"Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, Stemmelen C, Troxler TJ et al (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 20:4209\u20134223. \n                    https:\/\/doi.org\/10.1093\/hmg\/ddr348","journal-title":"Hum Mol Genet"},{"key":"1449_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1523\/JNEUROSCI.2712-13.2014","volume":"34","author":"G Skibinski","year":"2014","unstructured":"Skibinski G, Nakamura K, Cookson MR, Finkbeiner S (2014) Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J Neurosci 34:418\u2013433. \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.2712-13.2014","journal-title":"J Neurosci"},{"key":"1449_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.227587","volume":"355","author":"MJ Fell","year":"2015","unstructured":"Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y et al (2015) MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther 355:397\u2013409. \n                    https:\/\/doi.org\/10.1124\/jpet.115.227587","journal-title":"J Pharmacol Exp Ther"},{"key":"1449_CR33","doi-asserted-by":"publisher","first-page":"273ra15","DOI":"10.1126\/scitranslmed.aaa3634","volume":"7","author":"RN Fuji","year":"2015","unstructured":"Fuji RN, Flagella M, Baca M, S. Baptista MA, Brodbeck J, Chan BK, Fiske BK, Honigberg L et al (2015) Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci Transl Med 7:273ra15. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aaa3634","journal-title":"Sci Transl Med"},{"key":"1449_CR34","doi-asserted-by":"publisher","unstructured":"Purlyte E, Dhekne HS, Sarhan AR, Gomez R, Lis P, Wightman M, Martinez TN, Tonelli F et al (2017) Rab29 activation of the Parkinson\u2019s disease-associated LRRK2 kinase. EMBO J:e201798099. \n                    https:\/\/doi.org\/10.15252\/embj.201798099","DOI":"10.15252\/embj.201798099"},{"key":"1449_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080705","volume":"8","author":"MAS Baptista","year":"2013","unstructured":"Baptista MAS, Dave KD, Frasier MA, Sherer TB, Greeley M, Beck MJ, Varsho JS, Parker GA et al (2013) Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS One 8:e80705. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0080705","journal-title":"PLoS One"},{"key":"1449_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1042\/BJ20121772","volume":"456","author":"E Lobbestael","year":"2013","unstructured":"Lobbestael E, Zhao J, Rudenko IN, Beylina A, Gao F, Wetter J, Beullens M, Bollen M et al (2013) Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Biochem J 456:119\u2013128. \n                    https:\/\/doi.org\/10.1042\/BJ20121772","journal-title":"Biochem J"},{"key":"1449_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1042\/BJ20100483","volume":"430","author":"RJ Nichols","year":"2010","unstructured":"Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y et al (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson \u2019 s disease-associated mutations and regulates cytoplasmic localization. Biochem J 430:393\u2013404. \n                    https:\/\/doi.org\/10.1042\/BJ20100483","journal-title":"Biochem J"},{"key":"1449_CR38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1042\/BJ20100784","volume":"430","author":"N Dzamko","year":"2010","unstructured":"Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser 910 \/ Ser 935 , disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430:405\u2013413. \n                    https:\/\/doi.org\/10.1042\/BJ20100784","journal-title":"Biochem J"},{"key":"1449_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nchembio.538","volume":"7","author":"X Deng","year":"2011","unstructured":"Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP et al (2011) Characterization of a selective inhibitor of the Parkinson\u2019s disease kinase LRRK2. Nat Chem Biol 7:203\u2013205. \n                    https:\/\/doi.org\/10.1038\/nchembio.538","journal-title":"Nat Chem Biol"},{"key":"1449_CR40","doi-asserted-by":"publisher","unstructured":"Delbroek L, Van Kolen K, Steegmans L, da Cunha R, Mandemakers W, Daneels G, De Bock PJ, Zhang J et al (2013) Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation. J Pharm Biomed Anal 76:49\u201358. \n                    https:\/\/doi.org\/10.1016\/j.jpba.2012.12.002","DOI":"10.1016\/j.jpba.2012.12.002"},{"key":"1449_CR41","doi-asserted-by":"publisher","unstructured":"Vancraenenbroeck R, De Raeymaecker J, Lobbestael E, G Fangye, Maeyer MD, Voet A, Baekelandt V, Taymans J-M (2014) In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. Front Mol Neurosci 7(51). \n                    https:\/\/doi.org\/10.3389\/fnmol.2014.00051","DOI":"10.3389\/fnmol.2014.00051"},{"key":"1449_CR42","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1471-4159.2010.07105.x","volume":"116","author":"V Dani\u00ebls","year":"2011","unstructured":"Dani\u00ebls V, Vancraenenbroeck R, Law BMH, Greggio E, Lobbestael E, Gao F, de Maeyer M, Cookson MR et al (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem 116:304\u2013315. \n                    https:\/\/doi.org\/10.1111\/j.1471-4159.2010.07105.x","journal-title":"J Neurochem"},{"key":"1449_CR43","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/jgm.778","volume":"7","author":"M Geraerts","year":"2005","unstructured":"Geraerts M, Michiels M, Baekelandt V, Debyser Z, Gijsbers R (2005) Upscaling of lentiviral vector production by tangential flow filtration. J Gene Med 7:1299\u20131310. \n                    https:\/\/doi.org\/10.1002\/jgm.778","journal-title":"J Gene Med"},{"key":"1449_CR44","doi-asserted-by":"publisher","unstructured":"Chia R, Haddock S, Beilina A, Rudenko IN, Mamais A, Kaganovich A, Li Y, Kumaran R (2014) Phosphorylation of LRRK2 by casein kinase 1\u03b1 regulates trans-Golgi clustering via differential interaction with ARHGEF7. Nat Commun 5:5827. \n                    https:\/\/doi.org\/10.1038\/ncomms6827","DOI":"10.1038\/ncomms6827"},{"key":"1449_CR45","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.bbrc.2009.10.034","volume":"390","author":"E Ohta","year":"2009","unstructured":"Ohta E, Katayama Y, Kawakami F, Yamamoto M, Tajima K, Maekawa T, Iida N, Hattori S et al (2009) I2020T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson\u2019s disease, has a higher intracellular degradation rate than the wild-type molecule. Biochem Biophys Res Commun 390:710\u2013715. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2009.10.034","journal-title":"Biochem Biophys Res Commun"},{"key":"1449_CR46","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1523\/JNEUROSCI.0185-08.2008","volume":"28","author":"L Wang","year":"2008","unstructured":"Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X et al (2008) The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28:3384\u20133391. \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.0185-08.2008","journal-title":"J Neurosci"},{"key":"1449_CR47","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nn.3350","volume":"16","author":"SJ Orenstein","year":"2013","unstructured":"Orenstein SJ, Kuo S-H, Tasset I, Arias E, Koga H, Fernandez-Carasa I, Cortes E, Honig LS et al (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16:394\u2013406. \n                    https:\/\/doi.org\/10.1038\/nn.3350","journal-title":"Nat Neurosci"},{"key":"1449_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1042\/BCJ20170803","volume":"475","author":"Y Fan","year":"2018","unstructured":"Fan Y, Howden AJM, Sarhan AR, Lis P, Ito G, Martinez TN, Brockmann K, Gasser T et al (2018) Interrogating Parkinson\u2019s disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem J 475:23\u201344. \n                    https:\/\/doi.org\/10.1042\/BCJ20170803","journal-title":"Biochem J"},{"key":"1449_CR49","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1042\/BJ20100483","volume":"430","author":"RJ Nichols","year":"2010","unstructured":"Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y et al (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson\u2019s disease-associated mutations and regulates cytoplasmic localization. Biochem J 430:393\u2013404. \n                    https:\/\/doi.org\/10.1042\/BJ20100483","journal-title":"Biochem J"},{"key":"1449_CR50","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/onc.2010.627","volume":"30","author":"JK Cheong","year":"2011","unstructured":"Cheong JK, Hung NT, Wang H, Tan P, Voorhoeve PM, Lee SH, Virshup DM (2011) IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1\u03b4\/\u025b and Wnt\/\u03b2-catenin independent inhibition of mitotic spindle formation. Oncogene 30:2558\u20132569. \n                    https:\/\/doi.org\/10.1038\/onc.2010.627","journal-title":"Oncogene"},{"key":"1449_CR51","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.expneurol.2017.07.019","volume":"298","author":"AB West","year":"2017","unstructured":"West AB (2017) Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Exp Neurol 298:236\u2013245. \n                    https:\/\/doi.org\/10.1016\/J.EXPNEUROL.2017.07.019","journal-title":"Exp Neurol"},{"key":"1449_CR52","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1042\/BST20120128","volume":"40","author":"E Lobbestael","year":"2012","unstructured":"Lobbestael E, Baekelandt V, Taymans J-M (2012) Phosphorylation of LRRK2: from kinase to substrate. Biochem Soc Trans 40:1102\u20131110. \n                    https:\/\/doi.org\/10.1042\/BST20120128","journal-title":"Biochem Soc Trans"},{"key":"1449_CR53","doi-asserted-by":"publisher","unstructured":"De Wit T, Baekelandt V, Lobbestael E (2018) LRRK2 phosphorylation: behind the scenes. Neuroscience , 24, 486, 500 doi: \n                    https:\/\/doi.org\/10.1177\/1073858418756309","DOI":"10.1177\/1073858418756309"},{"key":"1449_CR54","doi-asserted-by":"publisher","first-page":"E4357","DOI":"10.1073\/pnas.1523708113","volume":"113","author":"G Guaitoli","year":"2016","unstructured":"Guaitoli G, Raimondi F, Gilsbach BK, G\u00f3mez-Llorente Y, Deyaert E, Renzi F, Li X, Schaffner A et al (2016) Structural model of the dimeric Parkinson\u2019s protein LRRK2 reveals a compact architecture involving distant interdomain contacts. Proc Natl Acad Sci U S A 113:E4357\u2013E4366. \n                    https:\/\/doi.org\/10.1073\/pnas.1523708113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1449_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1042\/BJ20120637","volume":"446","author":"IN Rudenko","year":"2012","unstructured":"Rudenko IN, Kaganovich A, Hauser DN, Beylina A, Chia R, Ding J, Maric D, Jaffe H et al (2012) The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson\u2019s disease is a partial loss-of-function mutation. Biochem J 446:99\u2013111. \n                    https:\/\/doi.org\/10.1042\/BJ20120637","journal-title":"Biochem J"},{"key":"1449_CR56","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/jnr.23331","volume":"92","author":"ID Greene","year":"2014","unstructured":"Greene ID, Mastaglia F, Meloni BP, West KA, Chieng J, Mitchell CJ, Gai WP, Boulos S (2014) Evidence that the LRRK2 ROC domain Parkinson\u2019s disease-associated mutants A1442P and R1441C exhibit increased intracellular degradation. J Neurosci Res 92:506\u2013516. \n                    https:\/\/doi.org\/10.1002\/jnr.23331","journal-title":"J Neurosci Res"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1449-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-018-1449-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1449-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T19:18:48Z","timestamp":1577387928000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-018-1449-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,27]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1007\/s12035-018-1449-2","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,27]]},"assertion":[{"value":"30 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were performed in accordance with the European Communities Council Directive of November 24, 1986 (86\/609\/EEC) and approved by the Bioethical Committee of the KU Leuven (Belgium).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}